1	Targeting	Target	B-VP	VBG	O	0	ROOT	0
2	TNF	TNF	B-NP	NN	B-protein	1	OBJ	0
3	for	for	B-PP	IN	O	1	VMOD	0
4	Treatment	Treatment	B-NP	NN	O	3	PMOD	19	Treatment
5	of	of	B-PP	IN	O	4	NMOD	0
6	Cancer	Cancer	B-NP	NN	O	8	NMOD	0
7	and	and	I-NP	CC	O	8	NMOD	0
8	Autoimmunity	Autoimmunity	I-NP	NN	O	5	PMOD	0
9	.	.	O	.	O	1	P	0

1	Tumor	Tumor	B-NP	NN	B-protein	3	NMOD	0
2	necrosis	necrosis	I-NP	NN	I-protein	3	NMOD	0
3	factor-alpha	factor-alpha	I-NP	NN	I-protein	7	SUB	0
4	(	(	O	(	O	6	DEP	0
5	TNF-alpha	TNF-alpha	B-NP	NN	B-protein	6	DEP	0
6	)	)	O	)	O	3	NMOD	0
7	was	be	B-VP	VBD	O	0	ROOT	0
8	first	first	I-VP	RB	O	7	VMOD	0
9	isolated	isolate	I-VP	VBN	O	7	VC	0
10	two	two	B-NP	CD	O	11	NMOD	0
11	decades	decade	I-NP	NNS	O	9	OBJ	0
12	ago	ago	B-ADVP	RB	O	13	PMOD	0
13	as	as	B-PP	IN	O	11	NMOD	0
14	a	a	B-NP	DT	O	16	NMOD	0
15	macrophageproduced	macrophageproduce	I-NP	VBN	B-protein	16	NMOD	0
16	protein	protein	I-NP	NN	I-protein	13	PMOD	0
17	that	that	B-NP	WDT	O	16	NMOD	0
18	can	can	B-VP	MD	O	17	SBAR	0
19	effectively	effectively	I-VP	RB	O	18	VMOD	0
20	kill	kill	I-VP	VB	O	18	VC	17	kill
21	tumor	tumor	B-NP	NN	B-cell_type	22	NMOD	0
22	cells	cell	I-NP	NNS	I-cell_type	20	OBJ	0
23	.	.	O	.	O	7	P	0

1	TNF-alpha	TNF-alpha	B-NP	NN	B-protein	2	SUB	0
2	is	be	B-VP	VBZ	O	0	ROOT	0
3	also	also	B-ADVP	RB	O	2	VMOD	0
4	an	an	B-NP	DT	O	6	NMOD	0
5	essential	essential	I-NP	JJ	O	6	NMOD	0
6	component	component	I-NP	NN	O	2	PRD	0
7	of	of	B-PP	IN	O	6	NMOD	0
8	the	the	B-NP	DT	O	10	NMOD	0
9	immune	immune	I-NP	JJ	O	10	NMOD	0
10	system	system	I-NP	NN	O	7	PMOD	0
11	and	and	O	CC	O	2	VMOD	0
12	is	be	B-VP	VBZ	O	2	VMOD	0
13	required	require	I-VP	VBN	O	12	VC	0
14	for	for	B-PP	IN	O	13	VMOD	0
15	hematopoiesis	hematopoiesis	B-NP	NN	O	14	PMOD	0
16	,	,	O	,	O	13	P	0
17	for	for	B-PP	IN	O	13	VMOD	0
18	protection	protection	B-NP	NN	O	17	PMOD	0
19	from	from	B-PP	IN	O	18	NMOD	0
20	bacterial	bacterial	B-NP	JJ	O	21	NMOD	0
21	infection	infection	I-NP	NN	O	19	PMOD	0
22	and	and	B-PP	CC	O	17	PMOD	0
23	for	for	B-PP	IN	O	17	PMOD	0
24	immune	immune	B-NP	JJ	O	25	AMOD	0
25	cell-mediated	cell-mediated	I-NP	JJ	O	26	NMOD	0
26	cytotoxicity	cytotoxicity	I-NP	NN	O	23	PMOD	0
27	.	.	O	.	O	2	P	0

1	Extensive	Extensive	B-NP	JJ	O	2	NMOD	0
2	research	research	I-NP	NN	O	6	SUB	0
3	,	,	O	,	O	2	P	0
4	however	however	B-ADVP	RB	O	6	VMOD	0
5	,	,	O	,	O	6	P	0
6	has	have	B-VP	VBZ	O	0	ROOT	0
7	revealed	reveal	I-VP	VBN	O	6	VC	0
8	that	that	B-SBAR	IN	O	7	VMOD	0
9	TNF-alpha	TNF-alpha	B-NP	NN	B-protein	10	SUB	0
10	is	be	B-VP	VBZ	O	8	SBAR	0
11	one	one	B-NP	CD	O	10	PRD	0
12	of	of	B-PP	IN	O	11	NMOD	0
13	the	the	B-NP	DT	O	15	NMOD	0
14	major	major	I-NP	JJ	O	15	NMOD	0
15	players	player	I-NP	NNS	O	12	PMOD	0
16	in	in	B-PP	IN	O	15	NMOD	0
17	tumor	tumor	B-NP	NN	O	18	NMOD	0
18	initiation	initiation	I-NP	NN	O	26	NMOD	17	initiation
19	,	,	O	,	O	26	P	0
20	proliferation	proliferation	B-NP	NN	O	26	NMOD	4	proliferation
21	,	,	O	,	O	26	P	0
22	invasion	invasion	B-NP	NN	O	26	NMOD	14	invasion
23	,	,	O	,	O	26	P	0
24	angiogenesis	angiogenesis	B-NP	NN	O	26	NMOD	3	angiogenesis
25	and	and	I-NP	CC	O	26	NMOD	0
26	metastasis	metastasis	I-NP	NN	O	16	PMOD	14	metastasis
27	.	.	O	.	O	6	P	0

1	The	The	B-NP	DT	O	3	NMOD	0
2	proinflammatory	proinflammatory	I-NP	JJ	O	3	NMOD	0
3	activities	activity	I-NP	NNS	O	4	SUB	0
4	link	link	B-VP	VBP	O	0	ROOT	0
5	TNF-alpha	TNF-alpha	B-NP	NN	B-protein	4	OBJ	0
6	with	with	B-PP	IN	O	4	VMOD	0
7	a	a	B-NP	DT	O	9	NMOD	0
8	wide	wide	I-NP	JJ	O	9	NMOD	0
9	variety	variety	I-NP	NN	O	6	PMOD	0
10	of	of	B-PP	IN	O	9	NMOD	0
11	autoimmune	autoimmune	B-NP	JJ	O	12	NMOD	0
12	diseases	disease	I-NP	NNS	O	10	PMOD	0
13	,	,	O	,	O	12	P	0
14	including	include	B-PP	VBG	O	12	NMOD	0
15	psoriasis	psoriasis	B-NP	NN	O	37	NMOD	0
16	,	,	O	,	O	37	P	0
17	inflammatory	inflammatory	B-NP	JJ	O	19	NMOD	0
18	bowel	bowel	I-NP	NN	O	19	NMOD	0
19	disease	disease	I-NP	NN	O	37	NMOD	0
20	,	,	O	,	O	37	P	0
21	rheumatoid	rheumatoid	B-NP	JJ	O	22	NMOD	0
22	arthritis	arthritis	I-NP	NN	O	37	NMOD	0
23	,	,	O	,	O	37	P	0
24	systemic	systemic	B-NP	JJ	O	25	NMOD	0
25	sclerosis	sclerosis	I-NP	NN	O	37	NMOD	0
26	,	,	O	,	O	37	P	0
27	systemic	systemic	B-NP	JJ	O	29	NMOD	0
28	lupus	lupus	I-NP	NN	O	29	NMOD	0
29	erythematosus	erythematosus	I-NP	NN	O	37	NMOD	0
30	,	,	O	,	O	37	P	0
31	multiple	multiple	B-NP	JJ	O	32	NMOD	0
32	sclerosis	sclerosis	I-NP	NN	O	37	NMOD	0
33	,	,	O	,	O	37	P	0
34	diabetes	diabetes	B-NP	NN	O	37	NMOD	0
35	and	and	O	CC	O	37	NMOD	0
36	ankylosing	ankylose	B-VP	VBG	O	37	NMOD	0
37	spondylitis	spondylitis	B-NP	NN	O	14	PMOD	0
38	.	.	O	.	O	4	P	0

1	Systemic	Systemic	B-NP	JJ	O	2	NMOD	0
2	inhibitors	inhibitor	I-NP	NNS	O	31	SUB	0
3	of	of	B-PP	IN	O	2	NMOD	0
4	TNF	TNF	B-NP	NN	B-protein	3	PMOD	0
5	such	such	B-PP	JJ	O	6	PMOD	0
6	as	as	I-PP	IN	O	2	NMOD	0
7	etanercept	etanercept	B-NP	NN	O	18	NMOD	0
8	(	(	O	(	O	10	DEP	0
9	Enbrel	Enbrel	B-NP	NN	O	10	DEP	0
10	)	)	O	)	O	7	NMOD	0
11	(	(	O	(	O	16	DEP	0
12	a	a	B-NP	DT	O	15	NMOD	0
13	soluble	soluble	I-NP	JJ	B-protein	15	NMOD	0
14	TNF	TNF	I-NP	NN	I-protein	15	NMOD	0
15	receptor	receptor	I-NP	NN	I-protein	16	DEP	0
16	)	)	O	)	O	7	NMOD	0
17	and	and	O	CC	O	18	NMOD	0
18	infliximab	infliximab	B-NP	NN	O	23	NMOD	0
19	(	(	O	(	O	21	DEP	0
20	Remicade	Remicade	B-NP	NN	O	21	DEP	0
21	)	)	O	)	O	18	NMOD	0
22	and	and	O	CC	O	23	NMOD	0
23	adalimumab	adalimumab	B-NP	NN	O	6	PMOD	0
24	(	(	O	(	O	26	DEP	0
25	Humira	Humira	B-NP	NN	O	26	DEP	0
26	)	)	O	)	O	23	NMOD	0
27	(	(	O	(	O	30	DEP	0
28	anti-TNF	anti-TNF	B-NP	JJ	B-protein	29	NMOD	0
29	antibodies	antibody	I-NP	NNS	I-protein	30	DEP	0
30	)	)	O	)	O	23	NMOD	0
31	have	have	B-VP	VBP	O	0	ROOT	0
32	been	be	I-VP	VBN	O	31	VC	0
33	approved	approve	I-VP	VBN	O	32	VC	0
34	for	for	B-PP	IN	O	33	VMOD	0
35	the	the	B-NP	DT	O	39	NMOD	0
36	treatment	treatment	I-NP	NN	O	39	NMOD	19	treatment
37	inflammatory	inflammatory	I-NP	JJ	O	39	NMOD	0
38	bowel	bowel	I-NP	NN	O	39	NMOD	0
39	disease	disease	I-NP	NN	O	44	NMOD	0
40	,	,	O	,	O	44	P	0
41	psoriasis	psoriasis	B-NP	NN	O	44	NMOD	0
42	and	and	O	CC	O	44	NMOD	0
43	rheumatoid	rheumatoid	B-NP	JJ	O	44	NMOD	0
44	arthritis	arthritis	I-NP	NN	O	34	PMOD	0
45	.	.	O	.	O	31	P	0

1	These	These	B-NP	DT	O	2	NMOD	0
2	drugs	drug	I-NP	NNS	O	6	SUB	0
3	,	,	O	,	O	6	P	0
4	however	however	B-ADVP	RB	O	6	VMOD	0
5	,	,	O	,	O	6	P	0
6	exhibit	exhibit	B-VP	VBP	O	0	ROOT	0
7	severe	severe	B-NP	JJ	O	9	NMOD	0
8	side	side	I-NP	NN	O	9	NMOD	0
9	effects	effect	I-NP	NNS	O	6	OBJ	0
10	and	and	O	CC	O	6	VMOD	0
11	are	be	B-VP	VBP	O	6	VMOD	0
12	expensive	expensive	B-ADJP	JJ	O	11	PRD	0
13	.	.	O	.	O	6	P	0

1	Hence	Hence	B-NP	RB	O	3	AMOD	0
2	orally	orally	I-NP	RB	O	3	AMOD	0
3	active	active	I-NP	JJ	O	4	NMOD	0
4	blockers	blocker	I-NP	NNS	O	0	ROOT	0
5	of	of	B-PP	IN	O	4	NMOD	0
6	TNF-alpha	TNF-alpha	B-NP	NN	B-protein	5	PMOD	0
7	that	that	B-NP	WDT	O	4	NMOD	0
8	are	be	B-VP	VBP	O	14	VMOD	0
9	safe	safe	B-NP	JJ	O	13	AMOD	0
10	,	,	I-NP	,	O	13	P	0
11	efficacious	efficacious	I-NP	JJ	O	13	NMOD	0
12	and	and	I-NP	CC	O	13	NMOD	0
13	inexpensive	inexpensive	I-NP	JJ	O	14	SUB	0
14	are	be	B-VP	VBP	O	7	SBAR	0
15	urgently	urgently	I-VP	RB	O	14	VMOD	0
16	needed	need	I-VP	VBN	O	14	VC	0
17	.	.	O	.	O	4	P	0

1	Numerous	Numerous	B-NP	JJ	O	2	NMOD	0
2	products	product	I-NP	NNS	O	10	NMOD	0
3	from	from	B-PP	IN	O	2	NMOD	0
4	fruits	fruit	B-NP	NNS	O	3	PMOD	0
5	,	,	O	,	O	10	P	0
6	vegetable	vegetable	B-NP	JJ	O	10	NMOD	0
7	and	and	I-NP	CC	O	10	NMOD	0
8	traditional	traditional	I-NP	JJ	O	10	NMOD	0
9	medicinal	medicinal	I-NP	JJ	O	10	NMOD	0
10	plants	plant	I-NP	NNS	O	11	SUB	0
11	have	have	B-VP	VBP	O	0	ROOT	0
12	been	be	I-VP	VBN	O	11	VC	0
13	described	describe	I-VP	VBN	O	12	VC	0
14	which	which	B-NP	WDT	O	13	VMOD	0
15	can	can	B-VP	MD	O	14	SBAR	0
16	suppress	suppress	I-VP	VB	O	15	VC	18	suppress
17	TNF	TNF	B-NP	NN	B-protein	18	NMOD	0
18	expression	expression	B-NP	NN	O	21	NMOD	9	expression
19	and	and	O	CC	O	21	NMOD	0
20	TNF	TNF	B-NP	NN	B-protein	21	NMOD	0
21	signaling	signaling	I-NP	NN	O	25	NMOD	0
22	but	but	O	CC	O	25	NMOD	0
23	their	their	B-NP	PRP$	O	25	NMOD	0
24	clinical	clinical	I-NP	JJ	O	25	NMOD	0
25	potential	potential	I-NP	NN	O	16	OBJ	0
26	is	be	B-VP	VBZ	O	11	VMOD	0
27	yet	yet	B-ADJP	RB	O	26	VMOD	0
28	uncertain	uncertain	I-ADJP	JJ	O	26	PRD	0
29	.	.	O	.	O	11	P	0

